Medicamen Organics Peer Comparison

NSE: MEDIORG

₹26.50

₹0.00 (0.00%)

As on 08-Sep-2026 15:24IST

Market cap

₹39 Cr

Revenue (TTM)

₹38 Cr

P/E Ratio

--

P/B Ratio

0.9

Div. Yield

0 %

Edit

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Market cap (₹ Cr)	39	36,517	30,699	16,829	15,207
Revenue (₹ Cr)	38	9,683	2,372	2,590	676
Net Profit (₹ Cr)	4.05	1,018.97	497.77	603.02	183.60
Net Margin (%)	10.57	10.47	20.72	22.63	26.06
RoE (%)	18.13	21.30	28.49	19.61	22.72
Price to Earnings	--	36.11	61.67	27.91	83.27
Price-To-Book	0.94	6.98	15.19	4.83	16.46

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Operating Revenue	38.19	7,896.00	1,476.84	2,386.88	502.00
Total Income	38.28	7,968.78	1,497.35	2,421.45	511.33
Total Expenditure	31.57	6,427.14	1,153.58	1,704.30	310.99
EBITDA	6.62	1,468.85	323.26	682.58	191.01
Depreciation	0.74	384.13	65.55	60.61	10.59
EBIT	5.88	1,084.73	257.71	621.98	180.42
Interest	0.54	175.78	8.30	2.41	6.90
Other Income	0.10	72.79	20.51	34.57	9.33
Exceptional Items	--	-10.38	76.40	--	--
Profit before Tax	5.43	971.35	346.33	654.13	182.85
Provision for Tax	1.38	263.88	86.22	168.50	44.12
Profit after Tax	4.05	707.47	260.11	485.63	138.73

Liabilities (₹ Cr)

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Shareholder's Funds	30.13	4,446.19	1,524.81	2,817.37	493.09
Minority Interest	0.35	195.37	--	--	--
Non-Current Liabilities	1.57	811.91	189.39	466.05	49.00
Current Liabilities	27.16	2,668.27	465.69	470.16	174.76
Total Liabilities	59.21	8,121.73	2,179.88	3,753.59	716.85

Assets (₹ Cr)

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Non-Current Assets	13.78	3,565.87	1,040.38	1,418.43	292.73
Current Assets	45.43	4,555.86	1,139.50	2,335.16	424.12
Total Assets	59.21	8,121.73	2,179.88	3,753.59	716.85
Total Debt*	12.35	731.70	136.01	0.00	135.25
Net Current Assets	18.28	1,887.59	673.81	1,865.00	249.36
Contingent Liabilities	2.46	393.94	8.97	4.82	0.10

Cashflow (₹ Cr)

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Cash From Operating Activities	-4.54	851.71	317.40	391.52	48.73
Cash Flow from Investing Activities	-2.35	-94.00	-298.16	-615.65	-78.76
Cash from Financing Activities	10.47	-813.96	24.96	-6.23	52.70
Net Cash Inflow / Outflow	3.58	-56.25	44.21	-230.35	22.67

Ratios

Profitability Ratios

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
ROCE (%)	16.97	22.49	23.45	25.50	35.83
ROE (%)	18.13	19.19	18.54	18.94	32.76
ROA (%)	8.29	8.94	12.97	13.34	22.55
EBIT Margin (%)	17.57	19.52	23.28	30.05	39.91
Net Margin (%)	10.57	8.88	17.37	20.06	27.13
Cash Profit Margin (%)	12.53	13.61	22.05	22.79	28.51

Growth Ratios

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Revenue Growth (%)	51.11	18.59	-5.24	4.54	9.30
EBIT Growth (%)	15.62	19.81	-27.65	4.50	6.24
Net Profit Growth (%)	54.22	34.10	-13.32	3.13	4.16
EPS Growth (%)	13.36	30.75	-13.32	3.12	4.01
Book Value Growth (%)	92.53	50.94	18.89	20.94	37.86

Valuation Ratios

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Price / Earnings	6.27	29.84	59.57	27.24	0.00
Price / Book Value	0.86	4.58	10.17	4.71	0.00
Dividend Yield (%)	0.00	0.28	0.10	0.46	--
EV/EBITDA	5.01	13.55	44.72	18.35	0.48
Market Cap (₹ Cr)	25.39	20,327.45	15,494.53	13,228.83	0.00

Solvency Ratios

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Debt to Equity	0.42	0.17	0.09	0.00	0.27
Short term debt to equity ratio	0.40	0.11	--	--	0.17
Current Ratio	1.67	1.71	2.45	4.97	2.43
Quick Ratio	1.40	0.98	1.62	3.53	1.69
Interest Coverage	11.00	6.53	42.74	271.97	27.49

Operating Efficiency Ratios

	Medicamen Organics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Debtors to sales (%)	67.70	25.36	21.38	40.63	36.92
Asset Turnover	0.78	1.01	0.74	0.66	0.85
Receivable days	203.36	87.83	85.17	132.12	114.95
Inventory Days	65.15	78.64	90.97	102.08	68.03
Payable days	286.26	174.97	137.94	133.54	133.44
Cash Conversion Cycle	-17.75	-8.50	38.21	100.66	49.53